Clinical value of pulmonary metastasectomy for thyroid malignancies: A systematic review

Pulmonary Metastasectomy for Thyroid Malignancies

  • Yusuf Dundar Assistant Professor
  • Quinton Mandle Department of Otolaryngology – Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI, USA
  • Julie Samantray Department of Internal Medicine, Division of Endocrinology, Wayne State University School of Medicine, Detroit, MI, USA
  • Jeffrey Hotaling Department of Otolaryngology – Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI, USA
  • Syed Rizvi Department of Otolaryngology – Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI, USA
  • John Cramer Department of Otolaryngology – Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI, USA
  • Ho-Sheng Lin Department of Otolaryngology – Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI, USA
  • Syed Naweed Raza Department of Otolaryngology – Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI, USA

Abstract

Background:There is currently no consensus on the role of pulmonary metastasectomy(PM) for thyroid malignancies. The main objective of this study is therefore to systematically determine if there is any survival benefit to PM and determine good candidates for metastasectomy.

Methods: A systematic review of relevant studies was performed, evaluating articles identified using the PubMed, Cochrane and MEDLINE databases according to PRISMA-guidelines.

Results:The initial literature search yielded 18 articles of which 7 met inclusion criteria. Only data on thyroid cancers were included in the systematic review. A total of 174 patients who underwent PM were analyzed. The mean age was 54.8(range: 10-90), and 52.5% of patients were female. The overall absolute 5-year survival rate was 67.7% (range: 32.5-84.0%) for patients undergoing PM.  The reported post-surgical complication rate overall was 14.4% and two peri-operative deaths were reported. Three papers reported the following as good prognostic factors: Papillary histology, younger age(<45), disease free interval>3 years, R0 resection, systematic lymphadenectomy, thyroglobulin <10 ng and thyroglobulin reduction >80% after metastasectomy.

Conclusion:This study is the first systematic review evaluating the clinical role of PM for thyroid cancer in the literature to date. PM may offer prolonged survival over traditional therapy for selected patients.

Published
2019-10-20
How to Cite
Dundar, Y., Mandle, Q., Samantray, J., Hotaling, J., Rizvi, S., Cramer, J., Lin, H.-S., & Raza, S. N. (2019). Clinical value of pulmonary metastasectomy for thyroid malignancies: A systematic review: Pulmonary Metastasectomy for Thyroid Malignancies. The Southwest Respiratory and Critical Care Chronicles, 7(31), 24-33. https://doi.org/10.12746/swrccc.v7i31.583